Leitfaden durch die Vielfalt des kutanen Lupus erythematodes

1. Durosaro O et al (2009) Incidence of cutaneous lupus erythematosus, 1965– 2005: a population-based study. Arch Dermatol 145:249–253 2. Jarukitsopa S et al (2015) Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res 67:817–828 3. Wenzel J etal (2005) Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 153:1011–1015 4. Grassi M, Capello F, Bertolino L, Seia Z, Pippione M (2009) Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis.Clin Exp Dermatol 34:910–914 5. Reich A, Meurer M, Viehweg A, Muller DJ (2009) Narrow-band UVB-induced externalization of selected nuclear antigens in keratinocytes: implications for lupus erythematosus pathogenesis. Photochem Photobiol 85:1–7 6. Scholtissek B et al (2017) Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus rythematosus. J Invest Dermatol 137:1484–1492 7. Sarkar MK et al (2018) Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermalderived interferon kappa. Ann Rheum Dis 77:1653–1664 8. Zhang Y-P, Wu J, Han Y-F, Shi Z-R, Wang L (2017) Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema. Autoimmun Rev 16:735–742 9. Zahn S et al (2011) Evidence for apathophysiological role of keratino cyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus. J Invest Dermatol 131:133–140 10. Wenzel J et al (2005) Enhanced type I interferon signaling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 205:435–442 11. Lauffer F et al (2018) Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis. J Invest Dermatol 38:1785–1794 12. Farkas L et al (2001) Plasmacytoid dendritic cells (natural interferon-alpha/ beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159:237–243 13. Safi R et al (2019) Investigating the presence of neutrophil extracellular traps in cutaneous lesions of different subtypes of lupus erythematosus. Exp Dermatol 28:1348–1352 14. Whitacre CC (2001) Sex differences in autoimmune disease. Nat Immunol 2:777–780 15. Durosaro O et al (2009) Incidence of cutaneous lupus erythematosus, 1965– 2005: a population-based study. Arch Dermatol 145:249–253 16. Khan D, Ansar Ahmed S (2016) The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. Front Immunol 6:635 17. Hersh AO, Arkin LM, Prahalad S (2016) Immunogenetics of cutaneous lupus erythematosus. Curr Opin Pediatr 28:470–475 18. Peschke K et al (2014) Deregulated type I IFN response in TREX1-associated familial chilblain lupus. J Invest Dermatol 134:1456–1459 19. Ravenscroft JC et al (2011) Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus. Am J Med GenetA 155A:235–237 20. Konig N et al (2017) Familial chilblain lupus due to again-of-function mutation in STING. Ann Rheum Dis 76:468–472 21. Kuhn A et al (2014) Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol 171:571–579 22. Vaglio A et al (2018) Drug-induced lupus: traditional and new concepts. Autoimmun Rev 17:912–918 23. Shovman O et al (2018) Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature. Clin Rheumatol 37:563–568 24. Levine D et al (2010) Cutaneous lupus erythematosus and anti-TNF-α therapy: a case report with review of the literature. J Drugs Dermatol 9:1283–1287 25. Quaglia M et al (2021) Viral infections and systemic lupus erythematosus: new players in an old story. Viruses 13:277 26. Battaglia M, Garrett-Sinha LA (2020) Bacterial infections in lupus: roles in promoting immune activation and in pathogenesis of the disease. J Transl Autoimmun 4:100078 27. Fernandez-Ruiz R et al (2020) COVID-19 inpatients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res. 232:13-36 28. Cornelius R, Pawlak CR et al (2003) Flares in patients with systemic lupus erythematosus are associated with daily psychological stress. Psychother Psychosom 72:159–165 29. Sontheimer RD (1997) The lexicon of cutaneous lupus erythematosus – A review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 6:84–95 30. Kuhn A, Landmann A (2014) The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 48–49:14–19 31. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725 32. Aringer M et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71:1400–1412 33. Kuhn A et al (2010) Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 163:83–92 34. AWMF (2020) S2k-Leitlinie „Diagnostik und Therapie des kutanen Lupus erythematodes“ (AWMF-Registernummer 013-060) 35. Roenigk HH et al (1980) Discoid lupus erythematosus: diagnostic features and evaluation of topical corticosteroid therapy. Cutis 25:281–285 36. Tzung TY et al (2007) Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, doubleblind, bilateral comparison study. Br J Dermatol 156:191–192 37. Tlacuilo-Parra A et al (2005) Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 44:1564–1568 38. Yokogawa N et al (2017) Effects of Hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol 69:791–799 39. Borik L et al (2019) Type IV allergy to antimalarials can mimic cutaneous manifestations of lupus erythematosus. J Eur Acad Dermatol Venereol 33:e94–e96 40. Chasset F, Frances C, Barete S, Amoura Z, Arnaud L (2015) Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of theliterature. J Am Acad Dermatol 72:634–639 41. Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T (2005) Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 153:157–162 42. Ruzicka T etal (1992) Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 127:513–518 43. Klebes M et al (2016) Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatology 232:91–96 44. Sadlier M et al (2012) Mycophenolate mofetil and hydroxychloroquine: an effective treatment for recalcitrant cutaneous lupus erythematosus. J Am Acad Dermatol 66:160–161 45. Chasset F, Tounsi T, Cesbron E, Barbaud A, Frances C, Arnaud L (2018) Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol 78:342–350.e4 46. Callen JP, Spencer LV, Burruss JB, Holtman J (1991) Azathioprine. An effective, corticosteroid-sparing therapy for patients Leitfaden durch die Vielfalt des kutanen Lupus erythematodes